Dante J. Pieramici

Medicine · Health Sciences

45h-index10.3kcitations178works23.52yr avg
OpenAlex↗ORCID↗Google Scholar↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Retinal Diseases and Treatments(104), Retinal Imaging and Analysis(57), Retinal and Optic Conditions(56), Retinal and Macular Surgery(33), Glaucoma and retinal disorders(27)

Publications166 total

MAGIC: Study Design and Rationale for the Phase 2 Clinical Trial of Faricimab for Non-Proliferative Diabetic Retinopathy
Ophthalmologica·2026Open Access
Reply to Comment on Phase 2 Study of the Anti-High Temperature Requirement A1 (HtrA1) Fab Galegenimab (FHTR2163) in Geographic Atrophy Secondary to Age-Related Macular Degeneration
American Journal of Ophthalmology·2025
Structural Updates to the Implant and Refill Needle of the Port Delivery Platform
Translational Vision Science & Technology·2025· 2 citedOpen Access
Phase 2 Study of the Anti-High Temperature Requirement A1 (HtrA1) Fab Galegenimab (FHTR2163) in Geographic Atrophy Secondary to Age-Related Macular Degeneration
American Journal of Ophthalmology·2025· 4 cited
Port Delivery System With Ranibizumab vs Monitoring in Nonproliferative Diabetic Retinopathy Without Macular Edema
JAMA Ophthalmology·2025· 8 citedOpen Access
Refillable Drug Reservoirs for Retinal Vascular Diseases
American Journal of Ophthalmology·2024· 2 cited
ReCLAIM-2: A Randomized Phase II Clinical Trial Evaluating Elamipretide in Age-related Macular Degeneration, Geographic Atrophy Growth, Visual Function, and Ellipsoid Zone Preservation
Ophthalmology Science·2024· 19 citedOpen Access
Anti-VEGF Pharmaceutical Prior Authorization in Retina Practices
JAMA Ophthalmology·2024· 3 citedOpen Access
Supplemental Intravitreal Ranibizumab Injections in Eyes Treated with the Port Delivery System with Ranibizumab in the Archway Trial
Ophthalmology Retina·2024
Gene therapy for neovascular age-related macular degeneration by subretinal delivery of RGX-314: a phase 1/2a dose-escalation study
The Lancet·2024· 92 cited
Safety and efficacy of ixoberogene soroparvovec in neovascular age-related macular degeneration in the United States (OPTIC): a prospective, two-year, multicentre phase 1 study
EClinicalMedicine·2023· 54 citedOpen Access
Pegcetacoplan for the treatment of geographic atrophy secondary to age-related macular degeneration (OAKS and DERBY): two multicentre, randomised, double-masked, sham-controlled, phase 3 trials
The Lancet·2023· 375 citedOpen Access
X-Ray Vision during Iodine-125 Plaque Radiation Treatment of a Choroidal Melanoma
Ophthalmology Retina·2022· 1 cited
BILATERAL PERIPAPILLARY CHOROIDAL NEOVASCULARIZATION IN AN OTHERWISE HEALTHY TEENAGER TREATED WITH ANTIVASCULAR ENDOTHELIAL GROWTH FACTOR INJECTIONS
Retinal Cases & Brief Reports·2022
Pharmacokinetics of the Port Delivery System with Ranibizumab in the Ladder Phase 2 Trial for Neovascular Age-Related Macular Degeneration
Ophthalmology and Therapy·2022· 13 citedOpen Access
Management of Key Ocular Adverse Events in Patients Implanted with the Port Delivery System with Ranibizumab
Ophthalmology Retina·2022· 14 citedOpen Access
Implant Insertion Procedure of the Port Delivery System With Ranibizumab: Overview and Clinical Pearls
Ophthalmic surgery, lasers & imaging retina·2022· 14 citedOpen Access
A Phase I, Single Ascending Dose Study of GEM103 (Recombinant Human Complement Factor H) in Patients with Geographic Atrophy
Ophthalmology Science·2022· 20 citedOpen Access
Traumatic Maculopathy
2022· 1 cited
Archway Randomized Phase 3 Trial of the Port Delivery System with Ranibizumab for Neovascular Age-Related Macular Degeneration
Ophthalmology·2021· 169 citedOpen Access
page 1 of 9Next →

Frequent Co-authors

Robert L. Avery(15), Alessandro Castellarin(12), Ma'an Nasir(12), Eugene de Juan(11), Melvin Rabena(9), Mark S. Humayun(9), Dilsher S. Dhoot(8), Gildo Y Fujii(7), Nathan Steinle(7), Robert F. See(6), Neil M. Bressler(5), Maurício Maia(5), Charles C. Wykoff(5), Michele Melia(5), Kah‐Guan Au Eong(5), Adam R. Glassman(4), Arshad M. Khanani(4), John A. Wells(4), Andrew Schachat(4), Lee M. Jampol(4)